# A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers

> **NCT02248077** · PHASE4 · WITHDRAWN · sponsor: **Cytomedix**

## Conditions studied

- Impaired Wound Healing

## Interventions

- **DEVICE:** AutoloGel
- **OTHER:** Usual and Customary Care (UCC)

## Key facts

- **NCT ID:** NCT02248077
- **Lead sponsor:** Cytomedix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2016-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was redesigned in collaboration with CMS before it started.
- **Last updated:** 2016-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248077, "A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02248077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*